FDA approves HIV-1 treatment
(According to Stock Exchange Zone)
GlaxoSmithKline announced on Tuesday that the United States Food and Drug Administration (FDA) has approved its two-drug regimen for the treatment of adult patients with HIV-1, the infection that causes AIDS. The FDA has therefore approved Dovato, a full-dose regimen of dolutegravir and lamivudine for the treatment of HIV-1 infection in adults – with no history of antiretroviral therapy or resistance to the other of these compounds. According to GSK, this medication will allow patients to treat their infection with as few drugs as possible. Dovato is also under review by the European Medicines Agency (EMA) and the regulatory authorities in Canada, Australia, Switzerland and South Africa.
Sexual health: how prevention has forgotten lesbians
(According to Lesinrocks.com)
Lack of information, clichés, biased perceptions of gynecos … The sexual health of lesbian and bisexual women is still too often neglected by the medical community. An invisibilisation that is not without consequences.
Maintaining the momentum of the AIDS response in the world
(According to UNAIDS)
During a visit to South Africa, UNAIDS Executive Director Michel Sidibé cautioned that the global response to AIDS is at an inflection point can be reversed unless urgent action is taken to achieve the 2020 targets and the ambitious goals set for the next decade.
They show why AIDS multiplies faster in people with TB
(According to The Dispatch)
World leader in research on tuberculosis and the biology of infections, the Institute of Pharmacology and Structural Biology of Toulouse has just distinguished itself through a study. In their basic research work, Toulouse researchers have shown that in patients with severe tuberculosis, the HIV virus spreads more easily using nanotubes between macrophages (host cells). “This work provides new insights as few teams are working on TB / HIV co-infection.”